PMID- 27181530
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20181202
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 55
IP  - 10
DP  - 2016
TI  - Interrelationship between the Myocardial Mass, Fibrosis, BNP, and Clinical 
      Outcomes in Hypertrophic Cardiomyopathy.
PG  - 1261-8
LID - 10.2169/internalmedicine.55.6480 [doi]
AB  - Objective Increased left ventricular mass (LVM) and LV fibrosis mass (LVFM) are 
      characteristics of hypertrophic cardiomyopathy (HCM). Additionally, a substantial 
      increase in the plasma B-type natriuretic peptide (BNP) level is observed. 
      Therefore, we investigated the interrelationship and clinical significances of 
      these parameters in a HCM cohort that underwent cardiac MRI (CMR). Methods 
      Patients with HCM (n=109) receiving regular outpatient treatment underwent CMR 
      and follow-up through 2015 from CMR examinations. The clinical outcome measures 
      were all-cause mortality, admission for worsening heart failure, and ventricular 
      tachycardia/fibrillation. Results The baseline body mass index (BMI), LV outflow 
      tract (LVOT) obstruction, New York Heart Association (NYHA) class, and increased 
      left atrial dimension (LAD) index were associated with the plasma BNP level. In 
      the CMR analysis, LVM and LVFM indices significantly correlated with the BNP 
      level (r=0.422 and 0.368, respectively), which were independent determinants 
      according to a multivariate analysis (p=0.009 and 0.023, respectively). A 
      Kaplan-Meier analysis during a median follow-up of 19.4 months showed that the 
      baseline LVM or LVFM index was not associated with the clinical outcomes. 
      However, the baseline BNP level was significantly associated with them (p<0.001). 
      In addition, a multivariate Cox proportional hazard analysis showed that plasma 
      BNP was an independent predictor for the clinical outcomes after adjusting for 
      age, sex, LVM, and LVFM. Conclusion The LVM and LVFM are determinants of the BNP 
      level independent of the BMI, LVOT obstruction, LAD, and NYHA class in patients 
      with HCM. However, plasma BNP may be a more sensitive integrated-marker for the 
      clinical outcomes than LVM or LVFM.
FAU - Miyaji, Yuki
AU  - Miyaji Y
AD  - Division of Cardiology, Department of Internal Medicine, Kindai University 
      Faculty of Medicine, Japan.
FAU - Iwanaga, Yoshitaka
AU  - Iwanaga Y
FAU - Nakamura, Takashi
AU  - Nakamura T
FAU - Yasuda, Masakazu
AU  - Yasuda M
FAU - Kawamura, Takayuki
AU  - Kawamura T
FAU - Miyazaki, Shunichi
AU  - Miyazaki S
LA  - eng
PT  - Journal Article
DEP - 20160515
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Biomarkers)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Cardiomyopathy, Hypertrophic/blood/*diagnosis/physiopathology
MH  - Female
MH  - Fibrosis
MH  - Heart Failure/epidemiology/*etiology
MH  - Heart Ventricles/*diagnostic imaging/physiopathology
MH  - Humans
MH  - Incidence
MH  - Japan/epidemiology
MH  - Kaplan-Meier Estimate
MH  - Magnetic Resonance Imaging, Cine
MH  - Male
MH  - Middle Aged
MH  - Myocardium/*pathology
MH  - Natriuretic Peptide, Brain/*blood
EDAT- 2016/05/18 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/05/17 06:00
PHST- 2016/05/17 06:00 [entrez]
PHST- 2016/05/18 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - 10.2169/internalmedicine.55.6480 [doi]
PST - ppublish
SO  - Intern Med. 2016;55(10):1261-8. doi: 10.2169/internalmedicine.55.6480. Epub 2016 
      May 15.